Aspira Women's Health OvaWatch

Aspira Women's Health has launched the OvaWatch ovarian cancer risk assessment test. OvaWatch leverages an AI-based algorithm to evaluate the malignancy risk of an adnexal mass following an initial clinical assessment of indeterminant or if it determines the mass to be benign. The test has a negative predictive value of 99 percent and helps clinicians decide whether surgery may be premature or unnecessary, Aspira said.